Physician profile
Richard Casey
NPI 1609890797
$2,374.92
in general payments reported to CMS, 2019-2025
22 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $227 · 2021: $522 · 2022: $564 · 2023: $505 · 2024: $219 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $297.74 | 2022-2025 | Catalys System, Tecnis Iol, Veritas Vision System |
| Sun Pharmaceutical Industries INC. | $252.62 | 2019-2025 | Xelpros, Cequa, Bromsite |
| Horizon Therapeutics Plc | $200.14 | 2021-2023 | Tepezza |
| Allergan, INC. | $173.12 | 2019-2022 | |
| Sight Sciences, INC. | $154.03 | 2020-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $150.85 | 2019-2021 | |
| Alcon Vision LLC | $141.98 | 2023-2024 | Clareon, Argos, Hydrus Microstent |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $138.90 | 2019-2021 | |
| Ivantis, INC | $135.39 | 2021 | |
| Dompe US, INC. | $119.23 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $112.35 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $106.36 | 2022-2025 | Miebo, Xiidra |
| Abbvie INC. | $81.58 | 2022-2023 | Lumigan |
| Oyster Point Pharma, INC. | $78.09 | 2022-2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $69.65 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn Operating Company LLC | $31.27 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $24.34 | 2025 | Xdemvy |
| Biotissue Holdings INC. | $23.08 | 2022 | |
| Harrow Eye, LLC | $21.72 | 2025 | Vevye |
| Welch Allyn | $21.67 | 2020 | |
| Topcon Healthcare Solutions, INC. | $20.51 | 2019 | |
| Amgen INC. | $20.30 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.